Newsmeme!
Discover News you didn't know existed
LEXINGTON, Mass.----Cubist Pharmaceuticals, Inc. , a leading acute care therapeutics company, announced today that it has begun dosing in the CONSERV™-2 clinical trial with ecallantide.
Reporter’s note: The author of this story is undergoing treatment for symptoms of chronic Lyme disease.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |